A novel two-step pretargeted RIT (pRIT) strategy, using a less immunogenic bispecific protein (028-Fc-C825) targeting both the CD38 antigen and the 90Y-DOTA ligand, along with 90Y-DOTA-biotin, significantly reduced tumor growth and prolonged survival in both MM and non-Hodgkin lymphoma (NHL) models [69]. The gene discussed is CD38; the disease is Miyoshi myopathy.